Peripheral immunity is associated with cognitive impairment after acute minor ischemic stroke and transient ischemic attack.
PanPan ZhaoGuiMei ZhangYongChun WangChunXiao WeiZiCheng WangWeiJie ZhaiYanXin ShenLin ShiSun LiPublished in: Scientific reports (2024)
Immunoinflammation is associated with the development of post-stroke cognitive impairment (PSCI), however, peripheral immunity has not been fully explored. We aimed to investigate the association between PSCI and peripheral immune indicators, including neutrophil, lymphocyte, and mononuclear percentages and counts; the systemic immune inflammation index; platelet-to-lymphocyte ratio; neutrophil-to-lymphocyte ratio (NLR); and lymphocyte-to-monocyte ratio. A total of 224 patients with acute minor ischemic stroke or transient ischemic attack with 6-12 months of follow-up were included. PSCI was defined as a Montreal Cognitive Assessment score < 22 during the follow-up period. We performed logistic regression, subgroup analyses based on age and sex, and further established predictive models. We found that increased innate immunity indicators (neutrophils, neutrophil percentage) increased the risk of PSCI, whereas increased adaptive immunity indicator (lymphocytes) were protective against PSCI, especially in patients aged 50-65 years. Neutrophil percentage and NLR improved the predictive efficacy of the models that included demographic, clinical, and imaging information, with the area under the curve increased from 0.765 to 0.804 and 0.803 (P = 0.042 and 0.049, respectively). We conducted a comprehensive analysis of peripheral immunity in PSCI, providing a novel perspective on the early detection, etiology, and treatment of PSCI.
Keyphrases
- peripheral blood
- cognitive impairment
- chemotherapy induced
- cerebral ischemia
- end stage renal disease
- ejection fraction
- oxidative stress
- newly diagnosed
- peritoneal dialysis
- dendritic cells
- prognostic factors
- endothelial cells
- patient reported outcomes
- mild cognitive impairment
- immune response
- brain injury
- photodynamic therapy
- open label
- placebo controlled